BioAge Labs’ (BIOA) Buy Rating Reiterated at BTIG Research

BTIG Research reissued their buy rating on shares of BioAge Labs (NASDAQ:BIOA) in a research note released on Monday morning,Benzinga reports.

Several other research firms have also recently weighed in on BIOA. UBS Group assumed coverage on shares of BioAge Labs in a report on Sunday, October 11th. They issued a “neutral” rating and a $8.00 price target on the stock. Jefferies Financial Group set a $21.00 price objective on BioAge Labs in a research note on Friday, July 31st. Wall Street Zen cut BioAge Labs from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 10th. Roth Capital restated a “buy” rating and set a $25.00 target price on shares of BioAge Labs in a research report on Wednesday, September 9th. Finally, Weiss Ratings upgraded BioAge Labs from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, October 26th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $33.00.

BioAge Labs Stock Up 1.6%

Shares of NASDAQ:BIOA opened at $5.87 on Monday. The company has a 50 day moving average of $6.76 and a 200 day moving average of $15.28. BioAge Labs has a 12 month low of $4.81 and a 12 month high of $25.95.

BioAge Labs (NASDAQ:BIOA) last posted its earnings results on Thursday, November 5th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.05). BioAge Labs had a negative return on equity of 31.42% and a negative net margin of 1,253.60%. The firm had revenue of $0.30 million during the quarter. On average, research analysts expect that BioAge Labs will post -2.59 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioAge Labs

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc bought a new position in shares of BioAge Labs in the 2nd quarter worth $84,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of BioAge Labs during the 3rd quarter worth $104,000. State of Wyoming bought a new stake in shares of BioAge Labs during the 2nd quarter worth $154,000. Bank of Nova Scotia bought a new stake in shares of BioAge Labs during the 1st quarter worth $180,000. Finally, The Manufacturers Life Insurance Company purchased a new position in BioAge Labs in the second quarter worth $234,000.

About BioAge Labs

BioAge Labs is a clinical-stage biopharmaceutical company developing medicines for metabolic diseases by targeting biological pathways associated with aging. Its research platform draws on human data to identify age-related mechanisms that may be relevant to disease and treatment. The company’s pipeline includes BGE-102, an investigational oral inhibitor of the NLRP3 protein, which is being developed for metabolic conditions. BioAge previously studied azelaprag, an apelin-receptor agonist, but discontinued its development after safety concerns arose in a clinical trial.